Skip to content

Advertisement

  • Poster presentation
  • Open Access

A toxicity-dependent feasibility bound for the escalation with overdose control approach in phase I cancer trials

  • 1,
  • 2 and
  • 1
Trials201516 (Suppl 2) :P233

https://doi.org/10.1186/1745-6215-16-S2-P233

  • Published:

Keywords

  • Posterior Probability
  • Maximum Tolerate Dose
  • Control Approach
  • Severe Toxicity
  • Cancer Trial

Phase I trials of anti-cancer therapies aim to identify a Maximum Tolerated Dose (MTD), defined as the dose that causes unacceptable toxicity in a target proportion of patients. In such trials, the dose given to patients is adapted as dose-response data are accrued and the next patient may receive a higher, lower, or identical dose to that of previous patients.

Both rule- and model-based methods have been proposed for conducting dose-escalation studies and recommending an MTD. The Escalation with Overdose Control (EWOC) approach is a model-based design where the dose assigned to the next patient is one that, given all available data, has a posterior probability of exceeding the MTD equal to a pre-specified value known as the feasibility bound. The aim is to conservatively dose-escalate and approach the MTD, avoiding severe overdosing early on in a trial. Methodological and applied research has considered the EWOC approach with the feasibility bound both fixed and varying throughout a trial, yet some of the methods may recommend incoherent dose-escalation; that is, the next patient may be recommend a higher dose even though patients being treated at the previous dose experienced severe toxicities.

To counter this, we propose a toxicity-dependent feasibility bound that guarantees coherent dose-escalation and incorporates the desirable features of other EWOC approaches. We show via detailed and comprehensive simulation studies that our approach provides improved MTD recommendation properties over the traditional EWOC approach, as well as comparable operating characteristics relative to modified EWOC approaches, whilst guaranteeing coherent dose-escalation.

Authors’ Affiliations

(1)
MRC Biostatistics Unit Hub for Trials Methodology Research, Cambridge, Cambridgeshire, UK
(2)
Strangeways Research Laboratory, University of Cambridge, Cambridge, Cambridgeshire, UK

Copyright

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement